Skip to main navigation Skip to search Skip to main content

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

  • Pianko, Stephen (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA HREC Reference Number: HREC/90249/MonH-2022-347462(v4)
NMA SSA Reference Number: SSA/90249/MonH-2023-357010(v2)
Monash Health Local Reference: RES-22-0000-633A
StatusActive
Effective start/end date17/03/23 → 19/03/28

Clinical Trial Phase

  • Phase II